All News
Risk of adverse outcomes in PsA pregnancies
More pre eclampsia
More Cesarian section
More preterms
By Dr.Chambers #RNL2023 @RheumNow https://t.co/LRiSSpv4Yj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Smoking *may* only ⬆️ risk of #RA if shared epitope present AND double positive
By @Janetbirdope #RNL2023 https://t.co/TG1hseVCsD
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
#RNL2023 Year in Review
@andreafava: urinary biomarkers in lupus nephritis
CD163, IL-16, CD206 decrease at 3 months.
Urinary biomarkers predict 1 year proteinuric response, esp in prolif LN.
Liquid biopsy as way to monitor instead of serial biopsies
@RheumNow https://t.co/baZt57Qjne
Eric Dein ericdeinmd ( View Tweet)
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment
@RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
HCQ levels in SLE
>500 ng/mL = 19x higher adherence
>750 ng/mL 67% lower odds of adherence
Higher levels with CKD
I use HCQ levels in all patients for monitoring at each visit
@RheumNow https://t.co/6yCefQdPU0
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Year in Review
COMPLETE-PsA: DMARDs for PsA!
LEF+MTX better than MTX alone, 78 total patients
PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO
More treatment discontinuations (10 vs 3) in combo group due to GI intolerance
@RheumNow https://t.co/3Al8PQmNli
Eric Dein ericdeinmd ( View Tweet)
PMR classification criteria by @anisha_dua @RheumNow #RNL2023
Bursal and biceps tenosynovitis gets one point in PMR classification criteria. https://t.co/Lj1X9mkgBz
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Eric Dein ericdeinmd ( View Tweet)
Should we be measuring HCQ levels?
- note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels
- adjust dose for pts with renal impairment
@RheumNow #RNL2023 https://t.co/JvaRJKJRPv
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Dr. Rachel Tate uptoTate ( View Tweet)
Could MTX every other week dosing be an option in patients with stable disease..?
#RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay gurdeep_dulay ( View Tweet)
Urinary biomarkers in lupus nephritis
@RheumNow and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology!
#RNL2023 https://t.co/l1gQgFhviI
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Year in Review by Dr. Cush and Dr. Kavanaugh
Combo biologic therapy?
Phase II study from GI colleagues for UC
Guselkumab + golimumab
- no additional safety concerns
- improved clinical response
- extrapolate to rheumatology use?
#RNL2023 @RheumNow https://t.co/DirAovm1AX
Robert B Chao, MD doctorRBC ( View Tweet)
✅ RheumNow Live 2023
#RNL2023 @RheumNow
Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq
Laurent ARNAUD Lupusreference ( View Tweet)
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 @RheumNow
Safer?
No lab monitoring
And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Beautiful summary of GPA management by Dr.Carol Langford #RNL2023 @RheumNow https://t.co/FCwKN9tovX
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
PMR lab studies by @anisha_dua @RheumNow #RNL2023
Majority of patients will have elevated inflammatory markers.
Rapid clinical response to low dose of steroid. https://t.co/AgdIJ5YbOu
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Some points to consider in relapsing PMR , by @anisha_dua @RheumNow #RNL2023
Elevated ESR and CRP rule out GCA.
Relapses are common with steroid tapering, especially below 5mg. https://t.co/D17mdly7z5
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)